{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:37:28Z","timestamp":1775821048753,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic kidney disease (CKD) patients with and without heart failure (HF) often present with hyperkalaemia (HK) leading to increased risk of hospitalisations, cardiovascular related events and cardiovascular-related mortality. Renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi) therapy, the mainstay treatment in CKD management, provides significant cardiovascular and renal protection. Nevertheless, its use in the clinic is often suboptimal and treatment is frequently discontinued due to its association with HK. We evaluated the cost-effectiveness of patiromer, a treatment known to reduce potassium levels and increase cardiorenal protection in patients receiving RAASi, in the UK healthcare setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov cohort model was generated to assess the pharmacoeconomic impact of patiromer treatment in regulating HK in patients with advanced CKD with and without HF. The model was generated to predict the natural history of both CKD and HF and quantify the costs and clinical benefits associated with the use of patiromer for HK management from a healthcare payer\u2019s perspective in the UK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Economic evaluation of patiromer use compared to standard of care (SoC) resulted in increased discounted life years (8.93 versus 8.67) and increased discounted quality-adjusted life years (QALYs) (6.36 versus 6.16). Furthermore, patiromer use resulted in incremental discounted cost of \u00a32,973 per patient and an incremental cost-effectiveness ratio (ICER) of \u00a314,816 per QALY gained. On average, patients remained on patiromer therapy for 7.7\u00a0months, and treatment associated with a decrease in overall clinical event incidence and delayed CKD progression. Compared to SoC, patiromer use resulted in 218 fewer HK events per 1,000 patients, when evaluating potassium levels at the 5.5\u20136\u00a0mmol\/l; 165 fewer RAASi discontinuation episodes; and 64 fewer RAASi down-titration episodes. In the UK, patiromer treatment was predicted to have a 94.5% and 100% chance of cost-effectiveness at willingness-to-pay thresholds (WTP) of \u00a320,000\/QALY and \u00a330,000\/QALY, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study highlights the value of both HK normalisation and RAASi maintenance in CKD patients with and without HF. Results support the guidelines which recommend HK treatment, e.g., patiromer, as a strategy to enable the continuation of RAASi therapy and improve clinical outcomes in CKD patients with and without HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03088-3","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T04:33:19Z","timestamp":1678336399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure"],"prefix":"10.1186","volume":"24","author":[{"given":"Thomas","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tray","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Ramirez","family":"de Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"6","key":"3088_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5414\/CNP62465","volume":"62","author":"C Esposito","year":"2004","unstructured":"Esposito C, Bellotti N, Fasoli G, Foschi A, Plati AR, Dal Canton A. Hyperkalemia-induced ECG abnormalities in patients with reduced renal function. Clin Nephrol. 2004;62(6):465\u20138.","journal-title":"Clin Nephrol"},{"issue":"3","key":"3088_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0025-7125(05)70536-8","volume":"81","author":"AK Mandal","year":"1997","unstructured":"Mandal AK. Hypokalemia and hyperkalemia. Med Clin North Am. 1997;81(3):611\u201339.","journal-title":"Med Clin North Am"},{"key":"3088_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0002-9149(02)02581-X","volume":"90","author":"C Obialo","year":"2002","unstructured":"Obialo C, Ofili E, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3088_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0749-0704(18)30329-4","volume":"7","author":"ME Williams","year":"1991","unstructured":"Williams ME. Hyperkalemia. Crit Care Clin. 1991;7(1):155\u201374.","journal-title":"Crit Care Clin"},{"issue":"5","key":"3088_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ekir.2021.02.038","volume":"6","author":"I Hougen","year":"2021","unstructured":"Hougen I, Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Tangri N. Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective Cohort. Kidney Int Rep. 2021;6(5):1309\u201316.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3088_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and\/or Diabetes. Am J Nephrol. 2017;46(3):213\u201321.","journal-title":"Am J Nephrol"},{"issue":"12","key":"3088_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156\u201362.","journal-title":"Arch Intern Med"},{"issue":"1","key":"3088_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12882-018-1007-1","volume":"19","author":"H Furuland","year":"2018","unstructured":"Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, Palaka E, Bennett H, Qin L. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrol. 2018;19(1):211.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3088_CR9","first-page":"c8","volume":"120","author":"J Hayes","year":"2012","unstructured":"Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012;120(1):c8-16.","journal-title":"Nephron Clin Pract"},{"issue":"10","key":"3088_CR10","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","volume":"109","author":"N Jain","year":"2012","unstructured":"Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510\u20133.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3088_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5114\/aoms.2014.42577","volume":"10","author":"J Khanagavi","year":"2014","unstructured":"Khanagavi J, Gupta T, Aronow WS, Shah T, Garg J, Ahn C, Sule S, Peterson S. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;10(2):251\u20137.","journal-title":"Arch Med Sci"},{"issue":"5","key":"3088_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2215\/CJN.05850809","volume":"5","author":"S Korgaonkar","year":"2010","unstructured":"Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010;5(5):762\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3088_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000437151","volume":"41","author":"GN Nakhoul","year":"2015","unstructured":"Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, Navaneethan SD. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease. Am J Nephrol. 2015;41(6):456\u201363.","journal-title":"Am J Nephrol"},{"issue":"2","key":"3088_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.ajkd.2014.03.012","volume":"64","author":"N Wiebe","year":"2014","unstructured":"Wiebe N, Klarenbach SW, Allan GM, Manns BJ, Pelletier R, James MT, Bello A, Hemmelgarn BR, Tonelli M. Potentially preventable hospitalization as a complication of CKD: a cohort study. Am J Kidney Dis. 2014;64(2):230\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3088_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73\u201387.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3088_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","volume":"42","author":"E Mishima","year":"2019","unstructured":"Mishima E, Haruna Y, Arima H. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. Hypertens Res. 2019;42(4):469\u201382.","journal-title":"Hypertens Res"},{"issue":"6","key":"3088_CR17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","volume":"27","author":"M Evans","year":"2011","unstructured":"Evans M, Bain SC, Hogan S, Bilous RW. participants obotCSG: Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrol Dial Transplant. 2011;27(6):2255\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3088_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","volume":"67","author":"AR Chang","year":"2016","unstructured":"Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, Matsushita K, Ballew SH, Coresh J, Grams ME. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension. 2016;67(6):1181\u20138.","journal-title":"Hypertension"},{"issue":"3","key":"3088_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.12990820","volume":"16","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Talarico R, Tangri N, Leon SJ, Bota SE, Rhodes E, Knoll GA, Sood MM. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence. Clin J Am Soc Nephrol. 2021;16(3):365\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3088_CR20","doi-asserted-by":"publisher","first-page":"R225","DOI":"10.1186\/cc11872","volume":"16","author":"JN An","year":"2012","unstructured":"An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, Lim CS. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):R225.","journal-title":"Crit Care"},{"key":"3088_CR21","unstructured":"Degli Esposti L, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Santoro A. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease]. G Ital Nefrol.\u00a02019;36(5):37-49."},{"issue":"1","key":"3088_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","volume":"6","author":"M Epstein","year":"2016","unstructured":"Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated\u00a0treatment guidelines and the real-world clinical\u00a0arena. Kidney Int Suppl (2011). 2016;6(1):20\u20138.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"22","key":"3088_CR23","doi-asserted-by":"publisher","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655.","journal-title":"J Am Heart Assoc"},{"key":"3088_CR24","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors.\u00a0Am J Manag Care. 2015;21(11 Suppl):S212-20."},{"issue":"5","key":"3088_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med. 2020;180(5):718\u201326.","journal-title":"JAMA Intern Med"},{"issue":"27","key":"3088_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"4-a Suppl","key":"3088_CR27","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2017.23.4-a.s2a","volume":"23","author":"M Polson","year":"2017","unstructured":"Polson M, Lord TC, Kangethe A, Speicher L, Farnum C, Brenner M, Oestreicher N, Alvarez P. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care Special Pharm. 2017;23(4-a Suppl):S2\u20139.","journal-title":"J Manag Care Special Pharm"},{"issue":"2","key":"3088_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","volume":"3","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385\u201393.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3088_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2014","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2014;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"3088_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314(2):151\u201361.","journal-title":"JAMA"},{"issue":"10","key":"3088_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057\u201365.","journal-title":"Eur J Heart Fail"},{"issue":"10208","key":"3088_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540\u201350.","journal-title":"Lancet"},{"issue":"5","key":"3088_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s41669-022-00357-z","volume":"6","author":"T Ward","year":"2022","unstructured":"Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland. PharmacoEconomics-open. 2022;6(5):757\u201371.","journal-title":"PharmacoEconomics-open"},{"key":"3088_CR34","unstructured":"Guidelines for the economic evaluation of health technologies in Ireland.\u00a0https:\/\/www.hiqa.ie\/sites\/default\/files\/2019-07\/HTA-Economic-Guidelines-2019.pdf."},{"key":"3088_CR35","unstructured":"NICE DSU Technical Support Documentation. http:\/\/nicedsu.org.uk\/technical-support-documents\/."},{"issue":"8","key":"3088_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2165\/11536310-000000000-00000","volume":"30","author":"M Nuijten","year":"2010","unstructured":"Nuijten M, Andress DL, Marx SE, Curry AS, Sterz R. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig. 2010;30(8):545\u201357.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"3088_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa1000552","volume":"363","author":"BA Cooper","year":"2010","unstructured":"Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609\u201319.","journal-title":"N Engl J Med"},{"key":"3088_CR38","unstructured":"NHS Blood and Transport: Annual report on kidney transplantation. 2019. https:\/\/www.odt.nhs.uk\/statisticsand-reports\/organ-specific-reports\/. Accessed 6 Aug 2022."},{"issue":"1","key":"3088_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehl382","volume":"28","author":"G Yao","year":"2007","unstructured":"Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert J-C, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42\u201351.","journal-title":"Eur Heart J"},{"issue":"13","key":"3088_CR40","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE. Hsu C-y: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305.","journal-title":"N Engl J Med"},{"issue":"5","key":"3088_CR41","doi-asserted-by":"publisher","first-page":"e001094","DOI":"10.1136\/bmjopen-2012-001094","volume":"2","author":"E Ford","year":"2012","unstructured":"Ford E, Adams J, Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open. 2012;2(5):e001094.","journal-title":"BMJ Open"},{"issue":"11","key":"3088_CR42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","volume":"113","author":"WC Levy","year":"2006","unstructured":"Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD. The Seattle Heart Failure Model prediction of survival in heart failure. Circulation. 2006;113(11):1424\u201333.","journal-title":"Circulation"},{"key":"3088_CR43","unstructured":"CSL Vifor: OPAL-HK Clinical study report. 2014."},{"issue":"6","key":"3088_CR44","first-page":"487","volume":"92","author":"AJ Viera","year":"2015","unstructured":"Viera AJ, Wouk N. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2015;92(6):487\u201395.","journal-title":"Am Fam Physician"},{"issue":"Suppl 1","key":"3088_CR45","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1097\/HJH.0000000000001278","volume":"35","author":"MR Weir","year":"2017","unstructured":"Weir MR, Mayo MR, Garza D, Arthur SA, Berman L, Bushinsky D, Wilson DJ, Epstein M. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017;35(Suppl 1):S57\u201363.","journal-title":"J Hypertens"},{"issue":"1","key":"3088_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12882-019-1250-0","volume":"20","author":"L Horne","year":"2019","unstructured":"Horne L, Ashfaq A, MacLachlan S, Sinsakul M, Qin L, LoCasale R, Wetmore JB. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. 2019;20(1):85.","journal-title":"BMC Nephrol"},{"issue":"5","key":"3088_CR47","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"3088_CR48","doi-asserted-by":"crossref","unstructured":"Krogager ML, Eggers-Kaas L, Aasbjerg K, Mortensen RN, K\u00f8ber L, Gislason G, et al. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J-Cardiovas Pharmacother. 2015;1(4):245-51.","DOI":"10.1093\/ehjcvp\/pvv026"},{"issue":"9215","key":"3088_CR49","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","volume":"355","author":"MD Flather","year":"2000","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moy\u00e9 L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575\u201381.","journal-title":"Lancet"},{"key":"3088_CR50","unstructured":"UK Renal Association. UK Renal registry 22nd Annual Report 2018. 2019. https:\/\/renal.org\/about-us\/who-weare\/uk-renal-registry. Accessed 15 Aug 2022."},{"key":"3088_CR51","unstructured":"National Institute for Health and Care Excellence: Clinical guideline [CG182]: Chronic kidney disease in adults: assessment and management. 2014. https:\/\/www.nice.org.uk\/guidance\/cg182. Accessed 20 July 2021."},{"issue":"6","key":"3088_CR52","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/ndt\/gfm870","volume":"23","author":"K Baboolal","year":"2008","unstructured":"Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting\u2014a multicentre study. Nephrol Dial Transplant. 2008;23(6):1982\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"3088_CR53","unstructured":"Department of Health: NHS reference costs 2018 to 2019. https:\/\/www.england.nhs.uk\/national-cost-collection\/. Accessed 2 Feb 2021."},{"issue":"04","key":"3088_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0266462313000433","volume":"29","author":"S Kent","year":"2013","unstructured":"Kent S, Briggs A, Eckermann S, Berry C. Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. Int J Technol Assess Health Care. 2013;29(04):435\u201342.","journal-title":"Int J Technol Assess Health Care"},{"key":"3088_CR55","volume-title":"Clinical guideline [CG125]: Chronic kidney disease (stage 5): peritoneal dialysis","author":"National Institute for Health and Care Excellence","year":"2011","unstructured":"National Institute for Health and Care Excellence. Clinical guideline [CG125]: Chronic kidney disease (stage 5): peritoneal dialysis. 2011."},{"key":"3088_CR56","doi-asserted-by":"crossref","unstructured":"Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, Bryant J. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. 2014.","DOI":"10.3310\/hta18560"},{"key":"3088_CR57","unstructured":"Curtis L. Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care. 2020. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/. Accessed 8 Dec 2016."},{"key":"3088_CR58","unstructured":"NICE guideline [NG45]: Routine preoperative tests for elective surgery. Appendix M. 2016. https:\/\/www.nice.org.uk\/guidance\/ng45. Accessed 8 Dec 2016."},{"issue":"27","key":"3088_CR59","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola V-P, Jankowska EA. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"key":"3088_CR60","unstructured":"Haymarket Media Group Ltd. Monthly Index of Medical Specialities. 2016. http:\/\/www.mims.co.uk\/. Accessed 16 Nov 2017."},{"key":"3088_CR61","unstructured":"National Institute for Health and Care Excellence: Technology appraisal guidance [TA599]: Sodium zirconium cyclosilicate for treating hyperkalaemia. In.; 2019."},{"key":"3088_CR62","unstructured":"British National Formulary [https:\/\/bnf.nice.org.uk\/]"},{"key":"3088_CR63","unstructured":"Drugs and pharmaceutical electronic market information (eMit) [https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit]"},{"issue":"3","key":"3088_CR64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/emj.17.3.188","volume":"17","author":"P Ahee","year":"2000","unstructured":"Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. J Accid Emerg Med. 2000;17(3):188\u201391.","journal-title":"J Accid Emerg Med"},{"issue":"12","key":"3088_CR65","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","volume":"36","author":"LS Weisberg","year":"2008","unstructured":"Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246\u201351.","journal-title":"Crit Care Med"},{"key":"3088_CR66","unstructured":"Clinical practice guidelines: Treatment of acute hyperkalaemia in adults [https:\/\/renal.org\/sites\/renal.org\/files\/RENAL%20ASSOCIATION%20HYPERKALAEMIA%20GUIDELINE%202020.pdf]"},{"key":"3088_CR67","unstructured":"Curtis L, Burns A. Unit Costs of Health and Social Care 2016. In. University of Kent 2016."},{"key":"3088_CR68","unstructured":"Scottish drug tariffs: drugs and preparations with tariff prices (Part 7, March 2021).\u00a0Personal Social Services Research Unit.\u00a0https:\/\/www.isdscotland.org\/Health-Topics\/Prescribing-and-Medicines\/Scottish-Drug-Tariff\/Drugs-and-Preparations-with-Tariff-Prices.asp."},{"issue":"6","key":"3088_CR69","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, Mcculloch CE, Bostrom A, Hsu C-Y, Bindman AB, Go AS, Chertow GM. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801\u20138.","journal-title":"Kidney Int"},{"issue":"11","key":"3088_CR70","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1185\/030079905X65277","volume":"21","author":"AJ Lee","year":"2005","unstructured":"Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin. 2005;21(11):1777\u201383.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3088_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","volume":"12","author":"A G\u00f6hler","year":"2009","unstructured":"G\u00f6hler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure\u2014Health States Based on New York Heart Association Classes and Number of Rehospitalizations. Value in Health. 2009;12(1):185\u20137.","journal-title":"Value in Health"},{"issue":"1","key":"3088_CR72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/089686080202200107","volume":"22","author":"K Sennfalt","year":"2002","unstructured":"Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis\u2013a cost-utility analysis. Perit Dial Int. 2002;22(1):39\u201347.","journal-title":"Perit Dial Int"},{"key":"3088_CR73","volume-title":"UK Renal Registry 8th Annual Report 2004","author":"UK Renal Association","year":"2004","unstructured":"UK Renal Association. UK Renal Registry 8th Annual Report 2004. 2004."},{"key":"3088_CR74","volume-title":"UK Renal Registry 23rd Annual Report 2021","author":"UK Renal Association","year":"2021","unstructured":"UK Renal Association. UK Renal Registry 23rd Annual Report 2021. 2021."},{"issue":"8","key":"3088_CR75","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/01.TP.0000438026.03958.7b","volume":"97","author":"A Karim","year":"2014","unstructured":"Karim A, Farrugia D, Cheshire J, Mahboob S, Begaj I, Ray D, Sharif A. Recipient Age and Risk for Mortality After Kidney Transplantation in England. Transplantation. 2014;97(8):832\u20138.","journal-title":"Transplantation"},{"key":"3088_CR76","unstructured":"NICE health technology evaluations: the manual.\u00a0https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741."},{"issue":"1","key":"3088_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-019-1228-y","volume":"20","author":"M Evans","year":"2019","unstructured":"Evans M, Palaka E, Furuland H, Bennett H, Linde C, Qin L, McEwan P, Bakhai A. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol. 2019;20(1):1\u201311.","journal-title":"BMC Nephrol"},{"issue":"12","key":"3088_CR78","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1080\/13696998.2018.1518239","volume":"21","author":"A Bakhai","year":"2018","unstructured":"Bakhai A, Palaka E, Linde C, Bennett H, Furuland H, Qin L, McEwan P, Evans M. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. J Med Econ. 2018;21(12):1172\u201382.","journal-title":"J Med Econ"},{"key":"3088_CR79","volume-title":"Patiromer for treating hyperkalaemia","author":"National Institute for Health and Care Excellence","year":"2020","unstructured":"National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia. London: Technology appraisal guidance TA623. National Institute for Health and Care Excellence; 2020."},{"issue":"4","key":"3088_CR80","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ehf2.12292","volume":"5","author":"B Pitt","year":"2018","unstructured":"Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN. ESC heart failure. 2018;5(4):592\u2013602.","journal-title":"ESC heart failure"},{"key":"3088_CR81","unstructured":"RELieving Increasing oEdema Due to Heart Failure (RELIEHF). Clinical Trial NCT04142788. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04142788"},{"issue":"11 Suppl","key":"3088_CR82","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"key":"3088_CR83","doi-asserted-by":"publisher","first-page":"n2079","DOI":"10.1136\/bmj.n2079","volume":"374","author":"A O\u2019Dowd","year":"2021","unstructured":"O\u2019Dowd A. Hospital bed occupancy rates in England reach dangerously high levels. BMJ. 2021;374:n2079.","journal-title":"BMJ"},{"issue":"1","key":"3088_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-020-01781-w","volume":"18","author":"R McCabe","year":"2020","unstructured":"McCabe R, Schmit N, Christen P, D\u2019Aeth JC, L\u00f8chen A, Rizmie D, Nayagam S, Miraldo M, Aylin P, Bottle A. Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. BMC Med. 2020;18(1):1\u201312.","journal-title":"BMC Med"},{"issue":"1","key":"3088_CR85","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12916-020-01781-w","volume":"18","author":"R McCabe","year":"2020","unstructured":"McCabe R, Schmit N, Christen P, D\u2019Aeth JC, L\u00f8chen A, Rizmie D, Nayagam S, Miraldo M, Aylin P, Bottle A, et al. Adapting hospital capacity to meet changing demands during the COVID-19 pandemic. BMC Med. 2020;18(1):329.","journal-title":"BMC Med"},{"key":"3088_CR86","unstructured":"Covid-19 Policy tracker 2020. \nhttps:\/\/www.health.org.uk\/news-and-comment\/charts-and-infographics\/covid-19-policy-tracker\n."},{"issue":"1","key":"3088_CR87","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12889-019-6526-6","volume":"19","author":"DA Martinez","year":"2019","unstructured":"Martinez DA, Zhang H, Bastias M, Feijoo F, Hinson J, Martinez R, Dunstan J, Levin S, Prieto D. Prolonged wait time is associated with increased mortality for Chilean waiting list patients with non-prioritized conditions. BMC Public Health. 2019;19(1):233.","journal-title":"BMC Public Health"},{"key":"3088_CR88","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.socscimed.2016.05.043","volume":"161","author":"G Moscelli","year":"2016","unstructured":"Moscelli G, Siciliani L, Tonei V. Do waiting times affect health outcomes? Evidence from coronary bypass. Soc Sci Med. 2016;161:151\u20139.","journal-title":"Soc Sci Med"},{"issue":"3","key":"3088_CR89","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.athoracsur.2003.05.007","volume":"77","author":"H Rexius","year":"2004","unstructured":"Rexius H, Brandrup-Wognsen G, Od\u00e9n A, Jeppsson A. Mortality on the waiting list for coronary artery bypass grafting: incidence and risk factors. Ann Thorac Surg. 2004;77(3):769\u201374.","journal-title":"Ann Thorac Surg"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03088-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T04:34:54Z","timestamp":1678336494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03088-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3088"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03088-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"20 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations for economic evaluations (CHEERS checklist. This article is based on previously conducted research and does not involve any new studies of human or animal subjects performed by any of the authors; as such ethics approval and consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ARdA and GB are employees of CSL Vifor. TW, TB and RDL are employees of HEOR Ltd. HEOR Ltd received fees from CSL Vifor in relation to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}